Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

MLA

van Ramshorst, Mette S., et al. “Toxicity of Dual HER2-Blockade with Pertuzumab Added to Anthracycline versus Non-Anthracycline Containing Chemotherapy as Neoadjuvant Treatment in HER2-Positive Breast Cancer: The TRAIN-2 Study.” Breast, vol. 29, Oct. 2016, pp. 153–59. EBSCOhost, https://doi.org/10.1016/j.breast.2016.07.017.

APA

van Ramshorst, M. S., van Werkhoven, E., Honkoop, A. H., Dezentjé, V. O., Oving, I. M., Mandjes, I. A., Kemper, I., Smorenburg, C. H., Stouthard, J. M., Linn, S. C., & Sonke, G. S. (2016). Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast, 29, 153–159. https://doi.org/10.1016/j.breast.2016.07.017

Chicago

van Ramshorst, Mette S., Erik van Werkhoven, Aafke H. Honkoop, Vincent O. Dezentjé, Irma M. Oving, Ingrid A. Mandjes, Inge Kemper, et al. 2016. “Toxicity of Dual HER2-Blockade with Pertuzumab Added to Anthracycline versus Non-Anthracycline Containing Chemotherapy as Neoadjuvant Treatment in HER2-Positive Breast Cancer: The TRAIN-2 Study.” Breast 29 (October): 153–59. doi:10.1016/j.breast.2016.07.017.